Medical Implications of Cannabinoids: What the Evidence Supports and Where Caution Is Needed
A comprehensive review found substantial evidence supporting cannabinoid efficacy for chronic pain and multiple sclerosis symptoms, while noting important adverse effects and the need for careful patient selection.
Quick Facts
What This Study Found
This review covered the medical evidence for cannabinoid therapeutics across multiple conditions. Chronic cancer pain, neuropathic pain, and certain MS symptoms had the strongest evidence supporting cannabinoid efficacy. For these conditions, well-characterized cannabinoid medications have met FDA standards.
The review emphasized patient selection as critical: cannabinoid therapy is most appropriate when standard treatments have failed for a debilitating condition. Physicians certifying medical cannabis must inform patients about acute effects (impaired memory, coordination, and judgment), potential chronic effects (cannabis use disorder, cognitive impairment, chronic bronchitis), and social risks (workplace issues, driving impairment).
The review also noted that novel approaches to manipulating the endocannabinoid system are being explored to maximize benefits while minimizing harmful effects, moving beyond simply administering THC.
Key Numbers
Chronic cancer and neuropathic pain and certain MS symptoms had substantial evidence. Cannabis use disorder, cognitive impairment, and chronic bronchitis are documented chronic risks. Acute risks include impaired memory, coordination, judgment, and increased motor vehicle accident risk.
How They Did This
Comprehensive narrative review published in Annals of Medicine, covering the history of medical cannabis, the endocannabinoid system, approved cannabinoid medications, medical conditions with evidence, adverse effects, and physician certification considerations.
Why This Research Matters
As medical cannabis programs expand, physicians need clear guidance on where the evidence supports use and how to counsel patients about risks. This review provides that framework, distinguishing between conditions with strong evidence and those with insufficient data.
The Bigger Picture
The review captures a pivotal moment in medical cannabis: sufficient evidence exists for specific conditions to justify use, but the evidence base does not support the broad claims often made by medical cannabis advocates. The emphasis on patient selection criteria and informed consent reflects the medical establishment's effort to integrate cannabinoid therapy responsibly.
What This Study Doesn't Tell Us
Narrative review format means the evidence selection and interpretation reflect the authors' perspective. The review predates several large clinical trials and regulatory changes. The rapid evolution of cannabis products (higher potency, new delivery methods) may not be fully captured.
Questions This Raises
- ?Has the evidence base for medical cannabis expanded since 2016 to include additional conditions?
- ?How do newer cannabinoid formulations compare to older ones for efficacy and safety?
- ?What is the optimal framework for physician certification of medical cannabis patients?
Trust & Context
- Key Stat:
- Chronic cancer/neuropathic pain and MS symptoms have "substantial evidence" for cannabinoid efficacy.
- Evidence Grade:
- Moderate evidence from a comprehensive narrative review synthesizing clinical trial data, approved indications, and risk assessments.
- Study Age:
- Published in 2016. The medical cannabis evidence landscape has evolved significantly with additional clinical trials and regulatory approvals.
- Original Title:
- Cannabinoids: Medical implications.
- Published In:
- Annals of medicine, 48(3), 128-41 (2016)
- Authors:
- Schrot, Richard J, Hubbard, John R
- Database ID:
- RTHC-01262
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What conditions have the strongest evidence for medical cannabis?
As of this 2016 review, chronic cancer pain, neuropathic pain, and certain multiple sclerosis symptoms (particularly spasticity) had the most substantial evidence. Other conditions had varying levels of support.
What are the main risks of medical cannabis?
Acute risks include impaired memory, coordination, and judgment. Chronic risks include developing cannabis use disorder, cognitive impairment, and chronic bronchitis from smoking. Social risks include workplace difficulties and increased motor vehicle accident risk.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01262APA
Schrot, Richard J; Hubbard, John R. (2016). Cannabinoids: Medical implications.. Annals of medicine, 48(3), 128-41. https://doi.org/10.3109/07853890.2016.1145794
MLA
Schrot, Richard J, et al. "Cannabinoids: Medical implications.." Annals of medicine, 2016. https://doi.org/10.3109/07853890.2016.1145794
RethinkTHC
RethinkTHC Research Database. "Cannabinoids: Medical implications." RTHC-01262. Retrieved from https://rethinkthc.com/research/schrot-2016-cannabinoids-medical-implications
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.